Prevention of secondary infections by interferon-gamma in ICU-acquired sustained immune suppression in France: study protocol of the PLATINIUM randomised trial

Key Points

• Prevention of secondary infections is the primary aim of the trial protocol, focusing on immune suppression in ICU settings.
• The trial involves randomised methods, assessing the role of interferon-gamma in patients with sustained immune suppression.
• This protocol targets patients in intensive care units who are at risk for secondary infections due to immune dysregulation.
• If successful, the findings may provide insights into new therapeutic approaches for preventing infections in vulnerable populations.